299 related articles for article (PubMed ID: 17312129)
1. Tumor cells loaded with alpha-galactosylceramide induce innate NKT and NK cell-dependent resistance to tumor implantation in mice.
Shimizu K; Goto A; Fukui M; Taniguchi M; Fujii S
J Immunol; 2007 Mar; 178(5):2853-61. PubMed ID: 17312129
[TBL] [Abstract][Full Text] [Related]
2. Innate Valpha14(+) natural killer T cells mature dendritic cells, leading to strong adaptive immunity.
Fujii S; Shimizu K; Hemmi H; Steinman RM
Immunol Rev; 2007 Dec; 220():183-98. PubMed ID: 17979847
[TBL] [Abstract][Full Text] [Related]
3. Glycolipid alpha-C-galactosylceramide is a distinct inducer of dendritic cell function during innate and adaptive immune responses of mice.
Fujii S; Shimizu K; Hemmi H; Fukui M; Bonito AJ; Chen G; Franck RW; Tsuji M; Steinman RM
Proc Natl Acad Sci U S A; 2006 Jul; 103(30):11252-7. PubMed ID: 16844772
[TBL] [Abstract][Full Text] [Related]
4. The interface between innate and acquired immunity: glycolipid antigen presentation by CD1d-expressing dendritic cells to NKT cells induces the differentiation of antigen-specific cytotoxic T lymphocytes.
Nishimura T; Kitamura H; Iwakabe K; Yahata T; Ohta A; Sato M; Takeda K; Okumura K; Van Kaer L; Kawano T; Taniguchi M; Nakui M; Sekimoto M; Koda T
Int Immunol; 2000 Jul; 12(7):987-94. PubMed ID: 10882410
[TBL] [Abstract][Full Text] [Related]
5. Targeted delivery of α-galactosylceramide to CD8α+ dendritic cells optimizes type I NKT cell-based antitumor responses.
Macho-Fernandez E; Cruz LJ; Ghinnagow R; Fontaine J; Bialecki E; Frisch B; Trottein F; Faveeuw C
J Immunol; 2014 Jul; 193(2):961-9. PubMed ID: 24913977
[TBL] [Abstract][Full Text] [Related]
6. Role of γδ T cells in α-galactosylceramide-mediated immunity.
Paget C; Chow MT; Duret H; Mattarollo SR; Smyth MJ
J Immunol; 2012 Apr; 188(8):3928-39. PubMed ID: 22412194
[TBL] [Abstract][Full Text] [Related]
7. The natural killer T (NKT) cell ligand alpha-galactosylceramide demonstrates its immunopotentiating effect by inducing interleukin (IL)-12 production by dendritic cells and IL-12 receptor expression on NKT cells.
Kitamura H; Iwakabe K; Yahata T; Nishimura S; Ohta A; Ohmi Y; Sato M; Takeda K; Okumura K; Van Kaer L; Kawano T; Taniguchi M; Nishimura T
J Exp Med; 1999 Apr; 189(7):1121-8. PubMed ID: 10190903
[TBL] [Abstract][Full Text] [Related]
8. NKT cells enhance CD4+ and CD8+ T cell responses to soluble antigen in vivo through direct interaction with dendritic cells.
Hermans IF; Silk JD; Gileadi U; Salio M; Mathew B; Ritter G; Schmidt R; Harris AL; Old L; Cerundolo V
J Immunol; 2003 Nov; 171(10):5140-7. PubMed ID: 14607913
[TBL] [Abstract][Full Text] [Related]
9. Cross-presentation of glycolipid from tumor cells loaded with alpha-galactosylceramide leads to potent and long-lived T cell mediated immunity via dendritic cells.
Shimizu K; Kurosawa Y; Taniguchi M; Steinman RM; Fujii S
J Exp Med; 2007 Oct; 204(11):2641-53. PubMed ID: 17923500
[TBL] [Abstract][Full Text] [Related]
10. Prolonged IFN-gamma-producing NKT response induced with alpha-galactosylceramide-loaded DCs.
Fujii S; Shimizu K; Kronenberg M; Steinman RM
Nat Immunol; 2002 Sep; 3(9):867-74. PubMed ID: 12154358
[TBL] [Abstract][Full Text] [Related]
11. Decreased expressions of CD1d molecule on liver dendritic cells in subcutaneous tumor bearing mice.
Tatsumi T; Takehara T; Yamaguchi S; Sasakawa A; Yamamoto M; Fujita Y; Miyagi T; Ohkawa K; Hayashi N
J Hepatol; 2008 Nov; 49(5):779-86. PubMed ID: 18760855
[TBL] [Abstract][Full Text] [Related]
12. DC therapy induces long-term NK reactivity to tumors via host DC.
Shimizu K; Fujii S
Eur J Immunol; 2009 Feb; 39(2):457-68. PubMed ID: 19180466
[TBL] [Abstract][Full Text] [Related]
13. Sequential production of interferon-gamma by NK1.1(+) T cells and natural killer cells is essential for the antimetastatic effect of alpha-galactosylceramide.
Smyth MJ; Crowe NY; Pellicci DG; Kyparissoudis K; Kelly JM; Takeda K; Yagita H; Godfrey DI
Blood; 2002 Feb; 99(4):1259-66. PubMed ID: 11830474
[TBL] [Abstract][Full Text] [Related]
14. α-Galactosylceramide and peptide-based nano-vaccine synergistically induced a strong tumor suppressive effect in melanoma.
Sainz V; Moura LIF; Peres C; Matos AI; Viana AS; Wagner AM; Vela Ramirez JE; S Barata T; Gaspar M; Brocchini S; Zloh M; Peppas NA; Satchi-Fainaro R; F Florindo H
Acta Biomater; 2018 Aug; 76():193-207. PubMed ID: 29940370
[TBL] [Abstract][Full Text] [Related]
15. IL-21 enhances dendritic cell ability to induce interferon-gamma production by natural killer T cells.
Maeda M; Yanagawa Y; Iwabuchi K; Minami K; Nakamaru Y; Takagi D; Fukuda S; Onoé K
Immunobiology; 2007; 212(7):537-47. PubMed ID: 17678711
[TBL] [Abstract][Full Text] [Related]
16. Detection and activation of human Valpha24+ natural killer T cells using alpha-galactosyl ceramide-pulsed dendritic cells.
Fujii S; Shimizu K; Steinman RM; Dhodapkar MV
J Immunol Methods; 2003 Jan; 272(1-2):147-59. PubMed ID: 12505720
[TBL] [Abstract][Full Text] [Related]
17. Therapeutic effect of alpha-galactosylceramide-loaded dendritic cells genetically engineered to express SLC/CCL21 along with tumor antigen against peritoneally disseminated tumor cells.
Matsuyoshi H; Hirata S; Yoshitake Y; Motomura Y; Fukuma D; Kurisaki A; Nakatsura T; Nishimura Y; Senju S
Cancer Sci; 2005 Dec; 96(12):889-96. PubMed ID: 16367909
[TBL] [Abstract][Full Text] [Related]
18. Gal-3 regulates the capacity of dendritic cells to promote NKT-cell-induced liver injury.
Volarevic V; Markovic BS; Bojic S; Stojanovic M; Nilsson U; Leffler H; Besra GS; Arsenijevic N; Paunovic V; Trajkovic V; Lukic ML
Eur J Immunol; 2015 Feb; 45(2):531-43. PubMed ID: 25359399
[TBL] [Abstract][Full Text] [Related]
19. A subset of NKT cells that lacks the NK1.1 marker, expresses CD1d molecules, and autopresents the alpha-galactosylceramide antigen.
Hameg A; Apostolou I; Leite-De-Moraes M; Gombert JM; Garcia C; Koezuka Y; Bach JF; Herbelin A
J Immunol; 2000 Nov; 165(9):4917-26. PubMed ID: 11046017
[TBL] [Abstract][Full Text] [Related]
20. Critical contribution of IFN-gamma and NK cells, but not perforin-mediated cytotoxicity, to anti-metastatic effect of alpha-galactosylceramide.
Hayakawa Y; Takeda K; Yagita H; Kakuta S; Iwakura Y; Van Kaer L; Saiki I; Okumura K
Eur J Immunol; 2001 Jun; 31(6):1720-7. PubMed ID: 11385616
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
